Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001580.
Sarcomas are a rare malignancy of mesenchymal tissues, comprizing a plethora of unique subtypes, with more than 60 types. The sheer heterogeneity of disease phenotype makes this a particularly difficult cancer to treat. Radiotherapy, chemotherapy and surgery have been employed for over three decades and, although effective in early disease (stages I-II), in later stages, where metastatic tumors are present, these treatments are less effective. Given the spectacular results obtained by cancer immunotherapy in a variety of solid cancers and leukemias, there is now a great interest in appliying this new realm of therapy for sarcomas. The widespread use of immunotherapy for sarcoma relies on immuno-profiling of subtypes, immunomonitoring for prognosis, preclinical studies and insight into the safety profile of these novel therapies. Herein, we discuss preclinical and clinical data highlighting how immunotherapy is being used in soft tissue sarcoma and bone sarcomas.
肉瘤是一种罕见的间充质组织恶性肿瘤，包含多种独特的亚型，超过 60 种。疾病表型的纯粹异质性使得这种癌症特别难以治疗。放射治疗、化学疗法和手术已经使用了三十多年，虽然在早期疾病（I-II 期）中有效，但在晚期，存在转移性肿瘤时，这些治疗效果较差。鉴于癌症免疫疗法在各种实体癌和白血病中取得的显著效果，现在人们对将这一新的治疗领域应用于肉瘤产生了极大的兴趣。肉瘤免疫疗法的广泛应用依赖于对亚型进行免疫分析、免疫监测预后、临床前研究以及对这些新型疗法的安全性特征的深入了解。在此，我们讨论了突出显示免疫疗法如何用于软组织肉瘤和骨肉瘤的临床前和临床数据。
